ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1538

Doppler Ultrasound Predicts Successful Discontinuation of Biological DMARDs in Rheumatoid Arthritis Patients in Sustained Clinical Remission

Lene Terslev1, Cecilie Hegaard Brahe2, Merete Hetland3, Stylianos Georgiadis4, Karen Ellegaard5, Lars Juul6, Uffe Døhn7, Viktoria Fana1, Torsten Møller1, Simon Krabbe1, Lykke Ørnbjerg1, Daniel Glinatsi1, Tuan Khai Huynh8, Natalia Manilo9, Dorte Vendelbo Jensen10, Karsten Asmussen9, Mikael Boesen11, Zoreh Rastiemadabadi12, Lone Morsel-Carlsen12, Jakob Møller13, Henrik Røgind1, Annette Hansen10, Jesper Nørregaard1, Søren Jacobsen14, Niels Steen Krogh15 and Mikkel Østergaard16, 1Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup., Copenhagen, Denmark, 2Center for Rheumatology and Spine diseases, Glostrup, Denmark, 3The DANBIO Registry, Rigshospitalet, Glostrup, Denmark, 4Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup., Glostrup, Denmark, 5The Parker Institute - Frederiksberg og Bispebjerg Hospitaler, Copenhagen, Denmark, 6Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Gentofte, Kobenhavn, Denmark, 7Center for Rheumatology and Spine Diseasesand COPECARE, Copenhagen, Denmark, 8Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, 9Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Frederiksberg, Copenhagen, Denmark, 10Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Gentofte, Copenhagen, Denmark, 11department of Radiology, Frederiksberg and Bispebjerg hospitals, Naerum, Denmark, 12Department of Radiology, Bispebjerg-Frederiksberg Hospital, Copenhagen, Denmark, 13Department of Radiology, Herlev and Gentofte Hospital, Herlev, Denmark, 14University of Copenhagen, Copenhagen, Denmark, 15ZiteLab ApS, Frederiksberg, Denmark, 16Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

Meeting: ACR Convergence 2020

Keywords: Disease Activity, rheumatoid arthritis, Ultrasound

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2020

Title: Imaging of Rheumatic Diseases Poster

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: There is an increasing interest in tapering or even discontinuing biological disease-modifying anti-rheumatic drugs (bDMARDs) in rheumatoid arthritis (RA) patients in sustained remission. The aim was to assess the potential role of ultrasound (US) for predicting successful tapering and successful discontinuation.

Methods: Patients with RA on bDMARDs in sustained disease activity score remission (DAS28-CRP < 2.6) and no radiographic progression the previous year were included(1). At baseline, clinical assessment, MRI and x-ray were performed as part of a standardized tapering regimen. Further, synovitis in 24 joints was scored 0-3 by US using the OMERACT scoring system for synovitis. At patient level, greyscale (GS), Doppler and the Global OMERACT/EULAR US Synovitis Score GLOESS synovitis sum scores were calculated. The bDMARD was reduced to 2/3 of standard dose at baseline, ½ dose after 16 weeks, and discontinued after 32 weeks. If flare occurred (defined as either DAS28-CRP≥2.6 and ΔDAS28-CRP≥1.2 from baseline, or erosive progression on X-ray and/or MRI) tapering was stopped and the dose escalated to the previous level. Final state of treatment was assessed after 2-years.

Logistic regression analyses were used to identify factors associated with successful tapering and successful discontinuation at 2 years follow-up. For all models, variables shown in Table 1 except MRI were included (separate models for ultrasound “24-joint-score” and “hands-only score”). Additional analyses including MRI variables (combined inflammation and combined damage) were performed. Missing data in independent variables were imputed with multiple imputation by chained equations (50 imputed datasets). Variables with p< 0.25 in univariate analyses were included in the initial multivariate model. Backward selection was performed to derive the final multivariate models using a significance level of 0.05.

Results: One-hundred-and-twenty-five patients completed 2-year follow-up.  At 2 years, 47 patients (38%) were back on full dose, 59 (46%) tapered to 2/3 or ½ dose and, 19 (15%) had discontinued the bDMARD.  A lower number of previous bDMARDs was an independent predictor for successful tapering (OR=0.54; p=0.006) (table 2). Negative IgM-RF (OR=0.26; p=0.012) and low Doppler sum score for 24 joints (OR=0.44; p=0.013) but not for hands alone, predicted successful discontinuation. Including MRI variables in the model did not affect the predictive value of Doppler sum score. GLOESS sum score was unable to predict successful tapering or discontinuation.

Conclusion: A low Doppler 24-joint sum score and negative IgM-RF at baseline were independent predictors for successful discontinuation of bDMARDs at 2-years’ follow-up. Low number of previous bDMARD, but not baseline US, predicted successful tapering.

Ref: 1. Brahe CH et al. Rheumatology (Oxford).2019;58:110-119.


Disclosure: L. Terslev, AbbVie, 8, MSD, 8, Novartis, 8, Roche, 8, Pfizer, 8, General Electric (GE), 8, Bristol Myers Squibb (BMS), 8, Janssen, 8; C. Hegaard Brahe, None; M. Hetland, Bristol-Myers Squibb Company, 2, AbbVie, 2, Roche, 2, Novartis, 2, Merck, 2, 5, Biogen, 2, 5, Pfizer, 2, 5, Eli Lilly, 5, Orion Pharma, 5, Celltrion, 5, Samsung Bioepis, 5; S. Georgiadis, None; K. Ellegaard, None; L. Juul, None; U. Døhn, None; V. Fana, None; T. Møller, None; S. Krabbe, AbbVie, 2, MSD, 2, Novartis, 2; L. Ørnbjerg, None; D. Glinatsi, None; T. Khai Huynh, None; N. Manilo, None; D. Jensen, None; K. Asmussen, Genmab, 1; M. Boesen, None; Z. Rastiemadabadi, None; L. Morsel-Carlsen, None; J. Møller, None; H. Røgind, None; A. Hansen, None; J. Nørregaard, None; S. Jacobsen, BMS, 2; N. Krogh, None; M. Østergaard, AbbVie, 2, 5, 8, Celgene, 2, 5, 8, Hospira, 5, 8, Janssen, 5, 8, Merck, 2, 5, 8, Novartis, 2, 5, 8, Novo Nordisk, 5, Orion, 5, 8, Regeneron, 5, Roche, 5, 8, UCB, 5, 8, Bristol-Myers Squibb, 2, 5, 8, Eli Lilly, 5, 8, Pfizer, 5, 8, Boehringer Ingelheim, 5, 8, Sandoz, 5, 8, Sanofi, 5, 8.

To cite this abstract in AMA style:

Terslev L, Hegaard Brahe C, Hetland M, Georgiadis S, Ellegaard K, Juul L, Døhn U, Fana V, Møller T, Krabbe S, Ørnbjerg L, Glinatsi D, Khai Huynh T, Manilo N, Jensen D, Asmussen K, Boesen M, Rastiemadabadi Z, Morsel-Carlsen L, Møller J, Røgind H, Hansen A, Nørregaard J, Jacobsen S, Krogh N, Østergaard M. Doppler Ultrasound Predicts Successful Discontinuation of Biological DMARDs in Rheumatoid Arthritis Patients in Sustained Clinical Remission [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/doppler-ultrasound-predicts-successful-discontinuation-of-biological-dmards-in-rheumatoid-arthritis-patients-in-sustained-clinical-remission/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/doppler-ultrasound-predicts-successful-discontinuation-of-biological-dmards-in-rheumatoid-arthritis-patients-in-sustained-clinical-remission/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology